ATE264113T1 - Verwendung von protein c zur behandlung von thrombozytopenischer purpura und hämolytisches urämisches syndrom - Google Patents
Verwendung von protein c zur behandlung von thrombozytopenischer purpura und hämolytisches urämisches syndromInfo
- Publication number
- ATE264113T1 ATE264113T1 AT99961896T AT99961896T ATE264113T1 AT E264113 T1 ATE264113 T1 AT E264113T1 AT 99961896 T AT99961896 T AT 99961896T AT 99961896 T AT99961896 T AT 99961896T AT E264113 T1 ATE264113 T1 AT E264113T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- thrombocytopenic purpura
- uremic syndrome
- hemolytic uremic
- provides
- Prior art date
Links
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 title abstract 3
- 206010043561 Thrombocytopenic purpura Diseases 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 abstract 1
- 101800004937 Protein C Proteins 0.000 abstract 1
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 abstract 1
- 101800001700 Saposin-D Proteins 0.000 abstract 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127090 anticoagulant agent Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000031169 hemorrhagic disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960000856 protein c Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4866—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11177098P | 1998-12-10 | 1998-12-10 | |
| PCT/US1999/028433 WO2000033867A1 (en) | 1998-12-10 | 1999-12-01 | Method of treating thrombocytopenic purpura and hemolytic uremic syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE264113T1 true ATE264113T1 (de) | 2004-04-15 |
Family
ID=22340356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99961896T ATE264113T1 (de) | 1998-12-10 | 1999-12-01 | Verwendung von protein c zur behandlung von thrombozytopenischer purpura und hämolytisches urämisches syndrom |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20010003740A1 (de) |
| EP (1) | EP1137432B1 (de) |
| JP (1) | JP2002531519A (de) |
| CN (1) | CN1329503A (de) |
| AT (1) | ATE264113T1 (de) |
| AU (1) | AU1838500A (de) |
| BR (1) | BR9915984A (de) |
| CA (1) | CA2351555A1 (de) |
| DE (1) | DE69916493T2 (de) |
| ES (1) | ES2219094T3 (de) |
| IL (1) | IL142249A0 (de) |
| WO (1) | WO2000033867A1 (de) |
| ZA (1) | ZA200102730B (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2002028416A1 (ja) * | 2000-09-30 | 2004-02-12 | 持田製薬株式会社 | 溶血性貧血の予防・治療剤 |
| CA2668187A1 (en) * | 2006-10-31 | 2008-06-19 | The Scripps Research Institute | Dosing regimen of activated protein c and variants having reduced anticoagulant activity |
| CN111035754A (zh) * | 2016-03-23 | 2020-04-21 | 兆科药业（合肥）有限公司 | 抗血小板溶栓素在制备治疗血栓性血小板减少性紫癜的药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5516650A (en) * | 1985-06-27 | 1996-05-14 | Zymogenetics, Inc. | Production of activated protein C |
| BR9809292A (pt) * | 1997-04-28 | 2000-07-04 | Lilly Co Eli | Métodos aperfeiçoados para o processamento de proteìna c ativada |
-
1999
- 1999-12-01 IL IL14224999A patent/IL142249A0/xx unknown
- 1999-12-01 AU AU18385/00A patent/AU1838500A/en not_active Abandoned
- 1999-12-01 DE DE69916493T patent/DE69916493T2/de not_active Expired - Fee Related
- 1999-12-01 ES ES99961896T patent/ES2219094T3/es not_active Expired - Lifetime
- 1999-12-01 CN CN99814123A patent/CN1329503A/zh active Pending
- 1999-12-01 WO PCT/US1999/028433 patent/WO2000033867A1/en not_active Ceased
- 1999-12-01 AT AT99961896T patent/ATE264113T1/de not_active IP Right Cessation
- 1999-12-01 BR BR9915984-8A patent/BR9915984A/pt not_active Application Discontinuation
- 1999-12-01 EP EP99961896A patent/EP1137432B1/de not_active Expired - Lifetime
- 1999-12-01 JP JP2000586357A patent/JP2002531519A/ja not_active Withdrawn
- 1999-12-01 CA CA002351555A patent/CA2351555A1/en not_active Abandoned
-
2000
- 2000-12-07 US US09/731,467 patent/US20010003740A1/en not_active Abandoned
-
2001
- 2001-04-03 ZA ZA200102730A patent/ZA200102730B/en unknown
-
2003
- 2003-06-24 US US10/602,936 patent/US20040087643A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1329503A (zh) | 2002-01-02 |
| ES2219094T3 (es) | 2004-11-16 |
| WO2000033867A1 (en) | 2000-06-15 |
| DE69916493T2 (de) | 2005-03-24 |
| EP1137432A1 (de) | 2001-10-04 |
| CA2351555A1 (en) | 2000-06-15 |
| ZA200102730B (en) | 2002-07-03 |
| EP1137432B1 (de) | 2004-04-14 |
| US20010003740A1 (en) | 2001-06-14 |
| US20040087643A1 (en) | 2004-05-06 |
| DE69916493D1 (de) | 2004-05-19 |
| IL142249A0 (en) | 2002-03-10 |
| BR9915984A (pt) | 2001-09-04 |
| AU1838500A (en) | 2000-06-26 |
| JP2002531519A (ja) | 2002-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| MY180762A (en) | Combination therapy comprising glucose reabsorption inhibitors and ppar modulators. | |
| ATE446097T1 (de) | Verwendung von uridin in kombination mit cholin zur behandlung von gedächtnisstörungen | |
| ATE234092T1 (de) | 2-alkylpyrrolidine | |
| DE69830751D1 (de) | Polyaromatische Verbindungen zur Behandlung von Herpes-Infektionen | |
| ATE364386T1 (de) | (s,s)-reboxetine zur behandlung von chronischen erschöpfungssyndrom | |
| DE69508192D1 (de) | Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen | |
| DE60330161D1 (de) | Rifalazil zur behandlung von infektionen mit clostridium difficile | |
| DE69831000D1 (de) | Verwendung von cytidin und cytosin-enthaltenden verbindungen zur behandlung von reizmittelgelgebrauch | |
| WO2021195470A3 (en) | Identification and use of compounds in the treatment or prevention of severe acute respiratory syndrome coronavirus 2 | |
| IL165988A0 (en) | Process for the preparation of fibrinogen | |
| IL142220A0 (en) | Method of treating viral hemorrhagic fever | |
| PT855916E (pt) | Composicao farmaceutica contendo um estimulador de activina ou inibina | |
| ATE283044T1 (de) | Compactin zur behandlung von entzündungen | |
| DE3686108D1 (de) | Verwendung von p-chlorophenoxyazetat von n,n-dimethylbiguanid zur behandlung von neuropathien und nervendegeneration. | |
| ATE264113T1 (de) | Verwendung von protein c zur behandlung von thrombozytopenischer purpura und hämolytisches urämisches syndrom | |
| MX9605072A (es) | Dispositivo dispensador para pretratamiento. | |
| ATE288498T1 (de) | Methoden zur inhibierung von helicobacter pylori | |
| ATE244008T1 (de) | Verwendung von makroliden zur behandlung von akuten lungenverletzungen | |
| DE69330465D1 (de) | Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4-aza-5 alpha-androst-1-en-3-one | |
| DE69905489D1 (de) | Protein c zur behandlung von sichelzellanämie und thalassämie | |
| DE60034110D1 (de) | Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien | |
| DE69930419D1 (de) | Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie | |
| NO984189L (no) | FremgangsmÕte for behandling av bipolar forstyrrelse | |
| GB0016362D0 (en) | Tetraspanin modulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |